Browsing Tag
IBRANCE
6 posts
Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?
Can Pfizer’s oncology and rare disease pipeline replace billions lost to patent cliffs? Explore how the drugmaker compares with Merck, Bristol Myers, and AstraZeneca.
Genentech’s Phase 3 study of inavolisib in breast cancer reveals positive results
Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the…
Roche’s inavolisib meets primary endpoint of PFS in Phase 3 breast cancer trial
Roche, a global leader in pharmaceuticals, announced positive results from its Phase III INAVO120 study, testing the investigational…
Zydus Lifesciences secures tentative FDA approval for Palbociclib Tablets
Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has announced that it has been granted tentative approval…
Olema Oncology partners with Pfizer for advanced breast cancer clinical trial
Olema Oncology, a leading California-based biopharmaceutical company focused on women’s cancer therapies, has entered a strategic partnership with…
Pfizer’s IBRANCE fails to meet primary endpoint in PENELOPE-B breast cancer trial
The latest results from Pfizer’s Phase 3 PENELOPE-B clinical trial have cast a shadow over the potential of…